MARCHF7

Across TCGA pan-cancer cohorts, MARCHF7 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MARCHF7 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MARCHF7 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated MARCHF7 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LIHC show a favorable association.

UCEC, COAD, and LUAD are the cancer types where MARCHF7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.937	0.431	.009	20	view →
COAD	OS	Median	II,III,IV	0.235	0.789	.001	13	view →
LUAD	OS	Median	III,IV	0.291	0.666	.035	9	view →
LIHC	DFS	Median	II,III,IV	1.000	0.314	.037	8	view →
SKCM	DFS	Median	III,IV	0.034	0.656	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MARCHF7–UCEC (DFS)

Open the UCEC breakdown →